The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy

Human Immunology

Volumn 75, Issue 4, 2014, Pages 289-296

  Zhang, Cuiping ^a   Xiao, Chunchun ^a   Wang, Peng ^a   Xu, Wenhua ^a   Zhang, Aimei ^a   Li, Qing ^a   Xu, Xiucai ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEMOGLOBIN A1C; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; URINALYSIS;

AGED; ALBUMINURIA; CASE-CONTROL STUDIES; CREATININE; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; RISK FACTORS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84895541424     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.02.007     Document Type: Article

References (46)

1. Caramori M.L., Mauer M. Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003, 12:273-282.
2. Remuzzi G., Schieppati A., Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002, 346:1145-1151.
3. Ritz E., Rychlik I., Locatelli F., Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999, 34:795-808.
4. Wolf G., Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 2003, 14:1396-1405.
5. Cooper M.E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001, 44:1957-1972.
6. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
7. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004, 34:785-796.
8. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19:433-442.
9. Rivero A., Mora C., Muros M., Garcia J., Herrera H., Navarro-Gonzalez J.F. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci (Lond) 2009, 116:479-492.
10. Wu C.C., Chen J.S., Lu K.C., Chen C.C., Lin S.H., Chu P., et al. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta 2010, 411:700-704.
11. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383:787-793.
12. Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996, 17:138-146.
13. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
14. Adkins B., Leclerc C., Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol 2004, 4:553-564.
15. Boissier M.C., Assier E., Falgarone G., Bessis N. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 2008, 75:373-375.
16. Cheng X., Yu X., Ding Y.J., Fu Q.Q., Xie J.J., Tang T.T., et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008, 127:89-97.
17. Ryba-Stanislawowska M., Skrzypkowska M., Mysliwiec M., Mysliwska J. Loss of the balance between CD4(+)Foxp3(+) regulatory T cells and CD4(+)IL17A(+) Th17 cells in patients with type 1 diabetes. Hum Immunol 2013, 74:701-707.
18. Zeng C., Shi X., Zhang B., Liu H., Zhang L., Ding W., et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl) 2012, 90:175-186.
19. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
20. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27.
21. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
22. Bloomgarden Z.T. American Diabetes Association annual meeting, 1997, and the Teczem Consultant Meeting. Diabetic nephropathy. Diabetes Care 1998, 21:315-319.
23. Wong C.K., Ho A.W., Tong P.C., Yeung C.Y., Kong A.P., Lun S.W., et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol 2007, 149:123-131.
24. Navarro-Gonzalez J.F., Mora-Fernandez C., Muros de Fuentes M., Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011, 7:327-340.
25. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
26. Zheng S.G., Wang J., Horwitz D.A. Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol 2008, 180:7112-7116.
27. Crome S.Q., Wang A.Y., Levings M.K. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 2010, 159:109-119.
28. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
29. Bending D., De la Pena H., Veldhoen M., Phillips J.M., Uyttenhove C., Stockinger B., et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009, 119:565-572.
30. Bradshaw E.M., Raddassi K., Elyaman W., Orban T., Gottlieb P.A., Kent S.C., et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol 2009, 183:4432-4439.
31. Honkanen J., Nieminen J.K., Gao R., Luopajarvi K., Salo H.M., Ilonen J., et al. IL-17 immunity in human type 1 diabetes. J Immunol 2010, 185:1959-1967.
32. Jagannathan-Bogdan M., McDonnell M.E., Shin H., Rehman Q., Hasturk H., Apovian C.M., et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol 2011, 186:1162-1172.
33. Arababadi M.K., Nosratabadi R., Hassanshahi G., Yaghini N., Pooladvand V., Shamsizadeh A., et al. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases?. Diabetes Res Clin Pract 2010, 87:33-37.
34. Roncarolo M.G., Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007, 7:585-598.
35. Costantino C.M., Baecher-Allan C.M., Hafler D.A. Human regulatory T cells and autoimmunity. Eur J Immunol 2008, 38:921-924.
36. Bluestone J.A., Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity?. Curr Opin Immunol 2005, 17:638-642.
37. Xu J., Su H.L., Wang J.H., Zhang C.H. Role of CD4+CD25+Foxp3+ regulatory T cells in type 2 diabetic nephropathy. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29:137-139.
38. Tiemessen M.M., Jagger A.L., Evans H.G., van Herwijnen M.J., John S., Taams L.S. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007, 104:19446-19451.
39. Liu G., Ma H., Qiu L., Li L., Cao Y., Ma J., et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol 2011, 89:130-142.
40. Lopes-Virella M.F., Virella G. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front Biosci 2003, 8:s750-68.
41. Westcott D.J., Delproposto J.B., Geletka L.M., Wang T., Singer K., Saltiel A.R., et al. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J Exp Med 2009, 206:3143-3156.
42. Wueest S., Rapold R.A., Schumann D.M., Rytka J.M., Schildknecht A., Nov O., et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J Clin Invest 2010, 120:191-202.
43. Moriwaki Y., Yamamoto T., Shibutani Y., Aoki E., Tsutsumi Z., Takahashi S., et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003, 52:605-608.
44. Mysliwska J., Zorena K., Semetkowska-Jurkiewicz E., Rachon D., Suchanek H., Mysliwski A. High levels of circulating interleukin-10 in diabetic nephropathy patients. Eur Cytokine Netw 2005, 16:117-122.
45. Zamauskaite A., Yaqoob M.M., Madrigal J.A., Cohen S.B. The frequency of Th2 type cells increases with time on peritoneal dialysis in patients with diabetic nephropathy. Eur Cytokine Netw 1999, 10:219-226.
46. Jefferson J.A., Shankland S.J., Pichler R.H. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008, 74:22-36.